-  Histologic documentation of women or men with node positive, HER2 negative, anatomic
             stage II or III breast carcinoma and high risk node negative (defined as estrogen
             receptor [ER] and progesterone receptor [PR] negative and tumor size > 2 cm) within
             one year of diagnosis and free of recurrence; patients with pN1mic are eligible; if
             neoadjuvant therapy was received, either initial clinical stage (determined by
             physical and or radiologic examination) or post-operative pathologic stage can be used
             for eligibility purposes, with the higher stage determining eligibility; histologic
             documentation of node positivity is required; bilateral breast cancers are allowed, as
             long as both cancers are HER2 negative and at least one of the cancers meets
             eligibility

          -  Any ER/progesterone receptor (PgR) status allowed

          -  Prior adjuvant treatment with chemotherapy and/or endocrine therapy, as determined by
             the treating physician, is allowed; the last dose of chemotherapy or radiation therapy
             must be at least 30 days prior to study registration; concurrent hormonal therapy will
             be allowed

          -  Regular nonsteroidal anti-inflammatory drug (NSAID)/aspirin use at any dose (including
             baby aspirin) (defined as >= 5 days per week) is allowed if aspirin and/or NSAIDs are
             stopped for 30 days prior to study entry and throughout the study period; participants
             will be encouraged to use acetaminophen for minor pain and fever

          -  Patients must be enrolled within 1 year after diagnosis

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Patients with a prior history of gastric/duodenal ulcers documented on endoscopy can
             be enrolled as long as the ulcers did not cause bleeding requiring a blood
             transfusion/major intervention; for patients who are Helicobacter pylori positive, a
             course of Helicobacter pylori eradication treatment must have been completed

          -  No history of gastrointestinal bleeding (GI) bleeding requiring a blood transfusion,
             endoscopic or operative intervention

          -  No history of any prior stroke (hemorrhagic or ischemic)

          -  No concurrent anticoagulation with warfarin or heparin/heparin analogues, clopidogrel,
             oral direct thrombin inhibitors, or direct factor XA inhibitors

          -  No history of atrial fibrillation or myocardial infarction

          -  No history of grade 4 hypertension, defined as hypertension resulting in
             life-threatening consequences (e.g., malignant hypertension, transient or permanent
             neurologic deficit, hypertensive crisis)

          -  No chronic (duration > 30 days) daily use of oral steroids

          -  No known allergy to aspirin

          -  No prior malignancy of any type (including ductal breast carcinoma in situ [DCIS])
             within the past 5 years except for current diagnosis of breast cancer, and any prior
             diagnosis of basal or squamous cell carcinoma of the skin or carcinoma in situ of the
             cervix; patients with a prior history of breast cancer greater than 5 years from study
             screening may participate in this study

          -  Concurrent enrollment on a non-chemotherapy treatment trial will be allowed, as long
             as that trial allows concurrent daily aspirin use